Micrometastasis in Gastrointestinal Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01919151 |
Recruitment Status : Unknown
Verified August 2013 by Oslo University Hospital.
Recruitment status was: Recruiting
First Posted : August 8, 2013
Last Update Posted : August 12, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Prognostic and predictive value of assessing the patients micrometastasis status in blood and bone marrow when diagnosed GI cancer. 2 different patient subgroups are currently studied, patients with cancer of the pancreas and patients with liver metastasis secondary to colorectal cancer.
Our hypothesis is that patients with detective circulating tumor cells in the blood or disseminated tumour cells in their bone marrow at diagnosis have a more advanced disease than negative patients. This information may be of therapeutic interest.
Condition or disease |
---|
Pancreatic Adenocarcinoma Colorectal Cancer |
Study Type : | Observational |
Estimated Enrollment : | 500 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | The Process of Metastasis in Colorectal Cancer Tumour Biology and Prognostic Factors in Pancreatic Cancer |
Study Start Date : | June 2008 |
Estimated Primary Completion Date : | December 2013 |
Estimated Study Completion Date : | December 2015 |

Group/Cohort |
---|
Gastrointestinal cancer patients
Patients with radiological suspected cancer in the pancreas Patients with radiological suspected colorectal liver metastasis
|
- Survival [ Time Frame: 5 year ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Gastrointestinal cancer patients:
- patients with suspected adenocarcinoma in the pancreas
- patients with liver metastases secondary to colorectal cancer
Inclusion Criteria:
- Histological proven adenocarcinoma of the pancreas
- Histological/radiological verified colorectal liver metastases
- Consent capable patient
- Signed written, informed consent
Exclusion Criteria:
1. Patient'history of other malignancy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01919151
Contact: Gro Wiedswang, MD,PhD | +4722119550 | uxgrie@ous-hf.no | |
Contact: Evi Faleide, MD,PhD | +4722118080 | UXEVAL@us-hf.no |
Norway | |
Oslo University Hospital | Recruiting |
Oslo, Norway, 0424 | |
Contact: Gro Wiedswang, MD,PhD +47 22119550 uxgrie@ous-hf.no | |
Principal Investigator: Gro Wiedswang, MD,PhD |
Study Chair: | Bjørn Atle Bjørnbeth, MD,PhD | Oslo University Hospital, Dep of Gastrointestinal surgery |
Responsible Party: | Oslo University Hospital |
ClinicalTrials.gov Identifier: | NCT01919151 |
Other Study ID Numbers: |
93-08172d6.2008.540 |
First Posted: | August 8, 2013 Key Record Dates |
Last Update Posted: | August 12, 2013 |
Last Verified: | August 2013 |
survival |
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases |